To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Galapagos Delivers Candidate Drug in GSK Alliance
Galapagos will now start scale-up chemistry and comprehensive safety evaluation to initiate Phase I clinical trials in early 2012.
This latest pre-clinical candidate is a small molecule that meets the chemical and biological criteria set by GSK for a potential new medicine. Galapagos will now start scale-up chemistry and comprehensive safety evaluation, with the aim to initiate Phase I clinical trials in early 2012.
"The arthritis alliance with GSK has been very fruitful in delivering promising candidate drugs," said Onno van de Stolpe, CEO of Galapagos. "In this alliance, we currently have two clinical trials, with plans to progress this new candidate into the clinic next year."
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
